SCHEMBL17469445

SCHEMBL17469445

CNCCN(C)Cc1n[nH]c2ccc(Oc3cccc(OC)c3)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FADS1 O60427 1/20 0.40
▸ HTR2A P28223 2/20 0.39
▸ PRMT1 Q99873 2/20 0.39
▸ HTR6 P50406 1/20 0.39
▸ PRMT5 O14744 1/20 0.38
▸ WDR77 Q9BQA1 1/20 0.38
▸ TTK P33981 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ HTR2B P41595 1/20 0.37
▸ HSP90AA1 P07900 2/20 0.36
▸ HSP90AB1 P08238 2/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ MTNR1A P48039 2/20 0.35
▸ MTNR1B P49286 2/20 0.35
▸ ACHE P22303 1/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ FLT3 P36888 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17469509 0.93 PRMT1 (0.43) FADS1HTR2APRMT1HTR6PRMT5
SCHEMBL17469504 0.92 HTR2A (0.44) FADS1HTR2APRMT1HTR6HTR2C
SCHEMBL16120045 0.90 TTK (0.39) PRMT1HTR6TTK
SCHEMBL17469470 0.90 HSP90AA1 (0.37) PRMT1HSP90AA1HSP90AB1
SCHEMBL17469453 0.89 PRMT1 (0.42) PRMT1SMN1; SMN2GSK3B
SCHEMBL16119992 0.89 FADS1 (0.41) FADS1HTR2APRMT1PRMT5WDR77
SCHEMBL17469469 0.87 PRMT5 (0.37) PRMT1HTR6PRMT5WDR77TTK
SCHEMBL17469513 0.86 PRMT5 (0.40) PRMT1PRMT5WDR77
SCHEMBL17469449 0.86 PRMT1 (0.37) HTR2APRMT1PRMT5WDR77TTK
SCHEMBL17469497 0.85 PRMT1 (0.38) FADS1HTR2APRMT1PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180105497-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2018-04-19 — — US disclosed
US-9765035-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2017-09-19 — — US disclosed
US-20160024017-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024017-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 FADS1 2222/4885HTR2A 4184/4885PRMT1 1/4885
US-20180105497-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 FADS1 2222/4885HTR2A 4184/4885PRMT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback